Deals empower Bicycle’s potential in radiopharma

UK-based Bicycle Therapeutics (Nasdaq: BCYC), a pharma company developing a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, has entered into a 15-year contract including an option to renew with the UK Nuclear Decommissioning Authority (NDA) for access to up to 400 tonnes of reprocessed uranium (RepU).

Since RepU continually regenerates, it provides a potentially sustainable supply of 212Pb. Bicycle intends to use the RepU provided by this agreement in its development of therapies.

Bicycle has also announced a collaboration with UK National Nuclear Laboratory (UKNNL), pursuant to which it plans to extract 228Th from the RepU obtained from NDA.